One of three disorders that fall under the umbrella of myeloproliferative neoplasms is myelofibrosis, which can lead to scarring and hardening inside the bone marrow. The exact cause of myelofibrosis is not known, but it has been linked to the JAK2 gene, which controls the production of blood cells. Doctors often treat the condition with the JAK1/2 inhibitor ruxolitinib.
Read the Full Article from GEN